Oxybutynin Unimedic (Oxybutynin Hydrochloride)

Oxybutynin, the active ingredient in Oxybutynin Unimedic, is an antispasmodic presented as a tablet for oral use. It treats symptoms of an overactive bladder, such as urgency, frequency, and urge incontinence, in adult patients. GNH USA supplies Oxybutynin Unimedic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Oxybutynin is used to manage bladder dysfunction by reducing involuntary muscle contractions.

- Overactive bladder: improves urinary urgency and frequency. - Urge urinary incontinence: decreases the number of incontinence episodes. - Neurogenic bladder dysfunction: lessens detrusor overactivity associated with neurological conditions.

Adverse reactions vary in frequency and severity.

Common Side Effects: - Dry mouth: reduced salivary flow. - Constipation: slowed gastrointestinal transit. - Blurred vision: transient visual disturbances. - Drowsiness: mild central nervous system depression. - Urinary retention: difficulty initiating urination.

Serious or Rare Side Effects: - Tachycardia: rapid heart rate requiring medical assessment. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Angle‑closure glaucoma: acute eye pain and visual loss. - Hepatic dysfunction: elevated liver enzymes. - Urinary retention leading to bladder over‑distension. - Persistent cognitive impairment.

Before prescribing Oxybutynin, consider patient‑specific factors and safety measures.

- Assess renal function: dose adjustment may be needed in renal impairment. - Evaluate hepatic function: monitor liver enzymes in patients with liver disease. - Review cardiac history: use cautiously in patients with tachyarrhythmias. - Monitor for glaucoma: patients with narrow‑angle glaucoma are at higher risk. - Avoid use in urinary retention: may exacerbate blockage. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Oxybutynin may interact with several drug classes; clinicians should review patient medication lists.

Major Interactions (Avoid): - Strong anticholinergic agents: additive anticholinergic burden. - CYP3A4 inhibitors: increased oxy‑exposure. - QT‑prolonging drugs: heightened risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Antihistamines: may enhance drowsiness.\n- Opioids: combined effect on urinary retention. - Metoclopramide: additive anticholinergic effects. - Digoxin: potential increase in serum levels. - Alcohol: may intensify central nervous system depression.